Researchers review the role of intratumoral microbiota in cancer development, suggesting its potential in predicting and treating various cancers.
Brise raises $20M; Taro shareholder criticizes Sun Pharma deal
Plus, news about Tarsus Pharmaceuticals and Biohaven: Brise Pharmaceuticals raises $20M: The funding comes from Shunxi Fund, Sherpa Healthcare Partners and Qiming Ventures, among other